HIV感染者中的肝细胞癌
本文综述HIV感染者(PLWH)肝细胞癌(HCC)的病理生理、筛查与管理现状。PLWH的慢性肝病和HCC风险更高,未接受积极抗癌治疗时预后较无HIV匹配对照更差;但 evolving 证据提示积极/治愈性治疗(含肝移植、局部治疗和全身治疗)在PLWH中获益与无HIV者相似,HIV控制良好不应成为抗癌治疗的障碍。PLWH历史上被排除在干预性临床试验之外,支持临床决策的证据多来自小型回顾性研究,肿瘤生物学及微环境是否受HIV影响尚不完全清楚。
要点
- PLWH的慢性肝病和HCC风险更高,与HIV和病毒性肝炎共享传播途径及HIV对肝病进展的直接和间接效应有关。
- 无积极抗癌治疗时,合并HCC的PLWH预后较无HIV匹配对照更差;但积极/治愈性治疗(含肝移植、局部和全身治疗)在PLWH中获益与无HIV者相似。
- HIV控制良好不应成为抗癌治疗的障碍;但PLWH历史上被排除在干预性临床试验之外,支持证据多来自小型回顾性研究。
核心结论
- HIV控制良好不应成为抗癌治疗的障碍;但PLWH历史上被排除在干预性临床试验之外,支持临床决策的证据多来自小型回顾性研究,肿瘤生物学及微环境是否受HIV影响尚不完全清楚。
研究设计与样本
- 本文为综述,总结PLWH中HCC的病理生理、筛查与管理现状,并讨论持续存在的挑战和照护差异。
主要发现
- PLWH的慢性肝病和HCC风险更高,与HIV和病毒性肝炎共享传播途径及HIV对慢性肝病和HCC进展的直接和间接效应有关。
- 无积极抗癌治疗时,合并HCC的PLWH预后较无HIV匹配对照更差。
- 积极/治愈性治疗(含肝移植、局部治疗和全身治疗)在PLWH中获益与无HIV者相似。
- PLWH历史上被排除在干预性临床试验之外,支持该人群临床决策的证据多来自小型回顾性研究。
- 肿瘤生物学及其微环境是否受HIV影响并影响治疗反应尚不完全清楚。
临床怎么用
- HIV控制良好不应成为抗癌治疗的障碍。
局限性
- PLWH历史上被排除在干预性临床试验之外,支持该人群临床决策的证据多来自小型回顾性研究。
- 肿瘤生物学及其微环境是否受HIV影响并影响治疗反应尚不完全清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
People living with HIV (PLWH) carry a higher risk of developing chronic liver disease and hepatocellular carcinoma (HCC). This relates to shared transmission pathways of HIV and viral hepatitis and a plethora of direct and indirect effects of HIV on the progression of chronic liver disease and HCC. In the absence of active cancer treatment, the prognosis of PLWH affected by HCC is worse than matched controls without HIV. However, evolving evidence suggests that active/curative treatments for HCC, including liver transplantation, locoregional treatment, and systemic treatment, confer similar benefit in PLWH as in people without HIV, underscoring that well-controlled HIV infection should not be a barrier to the delivery of cancer care. Nevertheless, PLWH have historically been excluded from interventional clinical trials, and most of the evidence supporting clinical decision making in this population comes from small retrospective studies, further complicating the management of PLWH affected by HCC. Furthermore, whether the biology of the tumour and its microenvironment is influenced by HIV and affects response to treatment is incompletely understood. In this review, we summarise the current understanding of pathophysiology, screening and management of HCC in PLWH and discuss the persisting challenges and disparities in care which may contribute to adverse clinical outcomes in PLWH.
引用
- Fulgenzi CAM, Dalla Pria A, Leone AG, et al. Hepatocellular carcinoma in people living with HIV. J Hepatol. 2025. PMID: 40316049. doi:10.1016/j.jhep.2025.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。